| Species |
Human |
| Protein Construction |
| His |
LOX1 (Ser61-Gln273)_x000D_
Accession # P78380-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
25.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-36 kDa under reduced condition and 60-70 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL.LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis. |
| Synonyms |
Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
